疑似急性冠脉综合征早期CT冠脉造影的成本效益分析
基于RAPID-CTCA随机试验的试验内经济分析及长期模型显示,早期CT冠脉造影(CTCA)与标准治疗相比,试验内 costs 与QALYs无显著差异,长期模型提示CTCA每例增加£481成本并损失0.025 QALYs,在£20 000/QALY阈值下具成本效益概率仅24%。
要点
- 试验内分析显示CTCA组 costs 较高(£7414 vs £6845)但差异无统计学意义(p=0.1521)。
- 长期模型显示CTCA每例增加£481成本并损失0.025 QALYs。
- 在£20 000/QALY阈值下,CTCA具成本效益的概率为24%。
核心结论
- 对疑似ACS患者常规使用早期CTCA不太可能是NHS资源的成本效益使用。
研究设计与样本
- 基于RAPID-CTCA随机试验的试验内经济分析,并结合二手数据源进行长期成本效益建模。
主要发现
- 试验内分析中,CTCA组 costs 为£7414,标准治疗组为£6845,均差£569(95%CI -£208至£1335;p=0.1521)。
- 试验内分析中,CTCA组QALYs为0.749,标准治疗组为0.758,均差-0.009(95%CI -0.026至0.010;p=0.377)。
- 长期经济分析提示CTCA平均每例治疗患者损失0.025 QALYs,并增加£481成本。
- 在£20 000/QALY阈值下,CTCA具成本效益的概率为24%。
临床怎么用
- 对于疑似ACS的中危患者,常规早期CTCA策略可能不是具有成本效益的资源使用方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the cost-effectiveness of early CT coronary angiography (CTCA) for intermediate risk patients with suspected acute coronary syndrome (ACS), compared with standard care METHODS: We performed within-trial economic analysis using data from the RAPID-CTCA randomised trial, and long-term modelling of cost-effectiveness using secondary data sources to estimate the cost-effectiveness of early CTCA compared with standard care for patients with suspected ACS attending acute hospitals in the UK. Cost-effectiveness was estimated as the incremental cost per quality-adjusted life year (QALY) gained, and the probability of each strategy being cost-effective at varying willingness-to-pay per QALY gained. RESULTS: The within-trial analysis showed that there were no demonstrable differences in costs or QALYs between early CTCA and standard care, with point estimates suggesting higher costs (£7414 vs £6845: mean difference £569, 95% CI -£208 to £1335; p=0.1521) and lower QALYs (0.749 vs 0.758, mean difference -0.009, 95% CI -0.026 to 0.010; p=0.377) in the CTCA arm. The long-term economic analysis suggested that, on average, CTCA was slightly less effective than standard care alone with 0.025 quality-adjusted life years lost per patient treated and was more expensive with additional costs of £481 per patient treated. At a threshold of £20 000 per QALY, CTCA has 24% probability of being cost-effective. CONCLUSIONS: There are no demonstrable differences in within-trial costs and QALYs, and long-term cost-effectiveness modelling suggested higher long-term costs with CTCA and uncertain effect on long-term QALYs, making routine use of CTCA for suspected ACS unlikely to be a cost-effective use of NHS resources.
引用
- Thokala, Goodacre, Oatey, et al. Cost-effectiveness of rapid assessment of potential ischaemic heart disease with CT coronary angiography. Heart. 2023. PMID: 36702543. doi:10.1136/heartjnl-2022-321211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。